Identification of novel Mt-Guab2 inhibitor series active against M. tuberculosis

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Usha, Veeraraghavan ^a   Hobrath, Judith V ^b   Gurcha, Sudagar S ^a   Reynolds, Robert C ^b   Besra, Gurdyal S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPOUND 5217501; COMPOUND 6655281; COMPOUND 7240567; COMPOUND 7383310; COMPOUND 7407367; COMPOUND 7409994; COMPOUND 7577905; COMPOUND 7610600; COMPOUND 7622922; COMPOUND 7741101; COMPOUND 7741703; COMPOUND 7756985; COMPOUND 7759844; COMPOUND 7913222; COMPOUND 9008726; INOSINATE DEHYDROGENASE INHIBITOR; ISONIAZID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERICIDAL ACTIVITY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SPECIFICITY; FEMALE; GUAB1 GENE; GUAB2 GENE; GUAB3 GENE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MAXIMUM TOLERATED DOSE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SINGLE DRUG DOSE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BINDING SITES; ENZYME INHIBITORS; HUMANS; IMP DEHYDROGENASE; KINETICS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; PROTEIN BINDING; RECOMBINANT PROTEINS; SMALL MOLECULE LIBRARIES; SUBSTRATE SPECIFICITY; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84859075290     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033886     Document Type: Article

References (59)

1. Dye C, Williams BG, (2010) The population dynamics and control of tuberculosis. Science 328: 856-61.
2. Yew WW, Sotgiu G, Migliori GB, (2011) Update in tuberculosis and nontuberculous mycobacterial disease 2010. Am J Respir Crit Care Med 184: 180-5.
3. Martinson NA, Hoffmann CJ, Chaisson RE, (2010) Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. Proc Am Thorac Soc 8: 288-93.
4. Harries AD, Dye C, (2006) Tuberculosis. Ann Trop Med Parasitol 100: 415-31.
5. Chiang CY, Centis R, Migliori GB, (2010) Drug-resistant tuberculosis: past, present, future. Respirology 15: 413-32.
6. Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, et al. (1996) Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85: 921-30.
7. Pimkin M, Pimkina J, Markham GD, (2009) A regulatory role of the bateman domain of IMP dehydrogenase in adenylate nucleotide biosynthesis. J Biol Chem 284: 7960-9.
8. Dobie F, Berg A, Boitz JM, Jardim A, (2007) Kinetic characterization of inosine monophosphate dehydrogenase of Leishmania donovani. Mol Biochem Parasitol 152: 11-21.
9. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-44.
10. Usha V, Gurcha SS, Lovering AL, Lloyd AJ, Papaemmanouil A, et al. (2010) Identification of novel diphenyl urea inhibitors of Mt-GuaB2 active against Mycobacterium tuberculosis. Microbiology 715: 290-9.
11. Shu Q, Nair V, (2008) Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery. Med Res Rev 28: 219-32.
12. Sassetti CM, Boyd DH, Rubin EJ, (2001) Comprehensive identification of conditionally essential genes in mycobacteria. Proc Natl Acad Sci USA 98: 12712-7.
13. Sassetti CM, Boyd DH, Rubin EJ, (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84.
14. Hedstrom L, (2009) IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev 109: 2903-28.
15. Gan L, Petsko GA, Hedstrom L, (2002) Crystal structure of a ternary complex of Tritrichomonas foetus inosine 5′-monophosphate dehydrogenase: NAD+ orients the active site loop for catalysis. Biochemistry 41: 13309-17.
16. Gilbert HJ, Lowe CR, Drabble WT, (1979) Inosine 5′-monophosphate dehydrogenase of Escherichia coli. Purification by affinity chromatography, subunit structure and inhibition by guanosine 5′-monophosphate, Biochem J 183: 481-94.
17. Cooney DA, Jayaram HN, Gebeyehu G, Betts CR, Kelley JA, et al. (1982) The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem Pharmacol 31: 2133-6.
18. Colby TD, Vanderveen K, Strickler MD, Markham GD, Goldstein BM, (1999) Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc Natl Acad Sci USA 96: 3531-6.
19. Goldstein BM, Colby TD, (1999) IMP dehydrogenase: structural aspects of inhibitor binding. Curr Med Chem 6: 519-36.
20. Franklin TJ, Cook JM, (1969) The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 113: 515-24.
21. Umejiego NN, Li C, Riera T, Hedstrom L, Striepen B, (2004) Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural, and dynamic properties that can be exploited for drug design. J Biol Chem 279: 40320-7.
22. Wang W, Hedstrom L, (1998) A potent "fat base" nucleotide inhibitor of IMP dehydrogenase. Biochemistry 37: 11949-52.
23. Arai M, Sobou M, Vilcheze C, Baughn A, Hashizume H, et al. (2008) Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent, Bioorg Med Chem 16: 6732-6.
24. Chen L, Wilson DJ, Xu Y, Aldrich CC, Felczak K, et al. (2010) Triazole-linked inhibitors of inosine monophosphate dehydrogenase from human and Mycobacterium tuberculosis. J Med Chem 53: 4768-78.
25. Digits JA, Hedstrom L, (1999) Species-specific inhibition of inosine 5′-monophosphate dehydrogenase by mycophenolic acid. Biochemistry 38: 15388-97.
26. Zhang R, Evans G, Rotella FJ, Westbrook EM, Beno D, et al. (1999) Characteristics and crystal structure of bacterial inosine-5′-monophosphate dehydrogenase. Biochemistry 38: 4691-700.
27. Park SJ, Joo WA, Choi J, Lee SH, Kim CW, (2004) Identification and characterization of inosine monophosphate dehydrogenase from Halobacterium salinarum Proteomics 4: 3632-41.
28. McMillan FM, Cahoon M, White A, Hedstrom L, Petsko GA, et al. (2000) Crystal structure at 2.4 Å resolution of Borrelia burgdorferi inosine 5′-monophosphate dehydrogenase: evidence of a substrate-induced hinged-lid motion by loop 6, Biochemistry 39: 4533-42.
29. Zhang XH, He KW, Duan ZT, Zhou JM, Yu ZY, et al. (2009) Identification and characterization of inosine 5-monophosphate dehydrogenase in Streptococcus suis type II, Microb Pathog 47: 267-73.
30. Zhou X, Cahoon M, Rosa P, Hedstrom L, (1997) Expression, purification, and characterization of inosine 5′-monophosphate dehydrogenase from Borrelia burgdorferi. J Biol Chem 272: 21977-81.
31. Riera TV, Wang W, Josephine HR, Hedstrom L, (2008) A kinetic alignment of orthologous inosine-5′-monophosphate dehydrogenases. Biochemistry 47: 8689-96.
32. Whitby FG, Luecke H, Kuhn P, Somoza JR, Huete-Perez JA, et al. (1997) Crystal structure of Tritrichomonas foetus inosine-5′-monophosphate dehydrogenase and the enzyme-product complex. Biochemistry 36: 10666-74.
33. Digits JA, Hedstrom L, (1999) Kinetic mechanism of Tritrichomonas foetus inosine 5′-monophosphate dehydrogenase. Biochemistry 38: 2295-306.
34. Prosise GL, Wu JZ, Luecke H, (2002) Crystal structure of Tritrichomonas foetus inosine monophosphate dehydrogenase in complex with the inhibitor ribavirin monophosphate reveals a catalysis-dependent ion-binding site. J Biol Chem 277: 50654-9.
35. Maddry JA, Ananthan S, Goldman RC, Hobrath JV, Kwong CD, et al. (2009) Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb) 89: 354-63.
36. Reynolds RC, Ananthan S, Faaleolea E, Hobrath JV, Kwong CD, et al. (2012) High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 92: 72-83.
37. Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, et al. (2009) High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv, Tuberculosis (Edinb) 89: 334-53.
38. Hedstrom L, Striepen B, (2007) IMP dehydrogenase inhibitors for treating mammalian gastrointestinal parasitic infections. PCT Int Appl WO2007143557 A2 20071213.
39. Hedstrom L, Cuny GD, (2010) Compounds and methods for treating mammalian gastrointestinal microbial infections. PCT Int Appl WO2010108187 A2 20100923.
40. Macpherson IS, Kirubakaran S, Gorla SK, Riera TV, D'Aquino JA, et al. (2010) The structural basis of Cryptosporidium specific IMP dehydrogenase inhibitor selectivity. J Am Chem Soc 132: 1230-1231.
41. Dhar TG, Shen Z, Guo J, Liu C, Watterson SH, et al. (2002) Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methy l-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity. J Med Chem 45: 2127-30.
42. Chen P, Norris D, Haslow KD, Murali Dhar TG, Pitts WJ, et al. (2003) Identification of novel and potent isoquinoline aminooxazole-based IMPDH inhibitors. Bioorg Med Chem Lett 13: 1345-8.
43. Watterson SH, Chen P, Zhao Y, Gu HH, Dhar TG, et al. (2007) Acridone-based inhibitors of inosine 5′- monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419). J Med Chem 50: 3730-42.
44. Macpherson IS, Kirubakaran S, Gorla SK, Riera TV, D'Aquino JA, et al. (2010) The structural basis of Cryptosporidium-specific IMP dehydrogenase inhibitor selectivity. J Am Chem Soc 132: 1230-1.
45. Maurya SK, Gollapalli DR, Kirubakaran S, Zhang M, Johnson CR, et al. (2009) Triazole inhibitors of Cryptosporidium parvum inosine 5′-monophosphate dehydrogenase. J Med Chem 52: 4623-30.
46. Sharling L, Liu X, Gollapalli DR, Maurya SK, Hedstrom L, et al. (2010) A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase in PLoS Negl Trop Dis.
47. Lenaerts AJ, Bitting C, Woolhiser L, Gruppo V, Marietta KS, et al. (2008) Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob Agents Chemother 52: 1513-5.
48. Rullas J, Garcia JI, Beltran M, Cardona PJ, Caceres N, et al. (2010) Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob Agents Chemother 54: 2262-4.
49. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, et al. (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178: 2243-7.
50. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM, (2003) Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 47: 783-5.
51. Hedstrom L, Wang CC, (1990) Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5′-monophosphate dehydrogenase: implications on enzyme mechanism. Biochemistry 29: 849-54.
52. Carr SF, Papp E, Wu JC, Natsumeda Y, (1993) Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 268: 27286-90.
53. O'Gara MJ, Lee CH, Weinberg GA, Nott JM, Queener SF, (1997) IMP dehydrogenase from Pneumocystis carinii as a potential drug target. Antimicrob Agents Chemother 41: 40-8.
54. Brennan PJ, Nikaido H, (1995) The envelope of mycobacteria. Annu Rev Biochem 64: 29-63.
55. Engelhardt H, Heinz C, Niederweis M, (2002) A tetrameric porin limits the cell wall permeability of Mycobacterium smegmatis. J Biol Chem 277: 37567-72.
56. Chaturvedi V, Dwivedi N, Tripathi RP, Sinha S, (2007) Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis. J Gen Appl Microbiol 53: 333-7.
57. Jarlier V, Nikaido H, (1994) Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 123: 11-8.
58. Li XZ, Zhang L, Nikaido H, (2004) Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 48: 2415-23.
59. Orme I, (2001) Search for new drugs for treatment of tuberculosis. Antimicrob Agents Chemother 45: 1943-6.